Levetiracetam

  • P. N. Patsalos
Chapter

Abstract

Calcium carbonate and aluminum hydroxide do not affect the pharmacokinetics of levetiracetam [1].

Keywords

Hydroxide Warfarin Digoxin Calcium Carbonate Meropenem 

References

  1. 1.
    Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707–24.PubMedCrossRefGoogle Scholar
  2. 2.
    Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res. 2001;46:93–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Mink S, Muroi C, Bjeljac M, Keller E. Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurismal subarachnoid haemorrhage. Clin Neurol Neurosurg. 2011;113:644–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85(2):77–85.PubMedCrossRefGoogle Scholar
  5. 5.
    Sabers A, Christensen J. No effect of oral contraceptives on the metabolism of levetiracetam. Epilepsy Res. 2011;95:277–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. 2001;47:55–63.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations